Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma Read more about Lion Biotechnologies Announces Positive Updated Data From NCI's Phase 2 Study of TIL Therapy in the Treatment of Metastatic Melanoma
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers Read more about Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers
Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi Read more about Lion Biotechnologies Announces the Departure of Dr. Laszlo Radvanyi
Lion Biotechnologies Announces Third Quarter 2015 Financial Results Read more about Lion Biotechnologies Announces Third Quarter 2015 Financial Results
Lion Biotechnologies Announces Agreement With WuXi AppTec to Increase TIL Manufacturing Capacity Read more about Lion Biotechnologies Announces Agreement With WuXi AppTec to Increase TIL Manufacturing Capacity
Lion Biotechnologies to Participate in Upcoming Investor Conferences Read more about Lion Biotechnologies to Participate in Upcoming Investor Conferences
Lion Biotechnologies Announces Selection for Addition to NASDAQ Biotechnology Index Read more about Lion Biotechnologies Announces Selection for Addition to NASDAQ Biotechnology Index
Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune Read more about Lion Biotechnologies Enters Clinical and Preclinical Research Collaboration With MedImmune
Lion Biotechnologies Announces Departure of Chief Financial Officer Read more about Lion Biotechnologies Announces Departure of Chief Financial Officer
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer Read more about Lion Biotechnologies Submits Investigational New Drug Application to Conduct Studies in Cervical, Head and Neck Cancer